Suppr超能文献

在核心针活检中诊断的乳腺原位癌的形态学亚型:临床病理特征和随访切除的发现。

Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.

机构信息

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Mod Pathol. 2021 Aug;34(8):1495-1506. doi: 10.1038/s41379-021-00796-9. Epub 2021 Apr 6.

Abstract

Lobular carcinoma in situ (LCIS) is currently classified as classic (CLCIS), florid (FLCIS), and pleomorphic (PLCIS). Given the rarity of FLCIS and PLCIS, information on their clinico-pathologic features and biologic potential remains limited. We evaluated the upgrade rates at excision of FLCIS and PLCIS diagnosed on inhouse core needle biopsy (CNB) and their clinical presentation and follow-up. Over a period of 11 and a half years, there were a total of 36 inhouse CNBs with pure PLCIS (n = 8), FLCIS (n = 24), or LCIS with pleomorphic features (LCIS-PF) (n = 4). The upgrade rates to invasive carcinoma or ductal carcinoma in situ (DCIS) were 25% for PLCIS (2/8), 17% for FLCIS (4/24), and 0% for LCIS-PF (0/4). The overall upgrade rate of PLCIS and FLCIS combined was 19% (6/32). All but one case (not upgraded at excision) were radiologic-pathologic concordant. Apocrine features, previously reported only in PLCIS, were also noted in FLCIS. HER2 overexpression was seen in 13% of cases. This study highlights the more aggressive biologic features of PLCIS and FLCIS compared to CLCIS and supports surgical management for these lesions.

摘要

乳腺小叶原位癌(LCIS)目前分为经典型(CLCIS)、增生型(FLCIS)和多形型(PLCIS)。鉴于 FLCIS 和 PLCIS 较为罕见,其临床病理特征和生物学潜能的信息仍然有限。我们评估了在切除经院内核心针活检(CNB)诊断的 FLCIS 和 PLCIS 时的升级率,以及它们的临床表现和随访情况。在 11 年半的时间里,共有 36 例经院内 CNB 诊断为单纯 PLCIS(n=8)、FLCIS(n=24)或具有多形性特征的 LCIS(LCIS-PF)(n=4)。侵袭性癌或导管原位癌(DCIS)的升级率为 PLCIS 25%(2/8)、FLCIS 17%(4/24)和 LCIS-PF 0%(0/4)。PLCIS 和 FLCIS 的总升级率为 19%(6/32)。除了 1 例(切除时未升级)外,所有病例均为影像学-病理学一致。先前仅在 PLCIS 中报道的大汗腺特征也在 FLCIS 中发现。HER2 过表达见于 13%的病例。本研究强调了 PLCIS 和 FLCIS 比 CLCIS 具有更具侵袭性的生物学特征,并支持对这些病变进行手术治疗。

相似文献

7
Pleomorphic Lobular Carcinoma In Situ: Imaging Features, Upgrade Rate, and Clinical Outcomes.
AJR Am J Roentgenol. 2018 Aug;211(2):462-467. doi: 10.2214/AJR.17.19088. Epub 2018 Jun 12.
8
Pleomorphic Lobular Carcinoma in Situ Diagnosed by Breast Core Biopsy: Clinicopathologic Features and Correlation With Subsequent Excision.
Clin Breast Cancer. 2018 Aug;18(4):e449-e454. doi: 10.1016/j.clbc.2017.10.004. Epub 2017 Oct 7.
9
10
Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast.
Breast J. 2018 Jan;24(1):66-69. doi: 10.1111/tbj.12843. Epub 2017 Sep 19.

引用本文的文献

2
Florid Lobular Carcinoma In Situ: Imaging Characteristics and Pathologic Upgrade Rates on Surgical Excision.
Breast J. 2025 Mar 30;2025:3580992. doi: 10.1155/tbj/3580992. eCollection 2025.
3
Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants.
Breast Cancer Res Treat. 2024 Jun;205(3):545-554. doi: 10.1007/s10549-024-07261-6. Epub 2024 Mar 12.
4
Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?
Ann Surg Oncol. 2023 Oct;30(10):6061-6069. doi: 10.1245/s10434-023-13899-1. Epub 2023 Jul 26.
5
Update on lobular lesions of the breast.
Histopathology. 2023 Jan;82(1):36-52. doi: 10.1111/his.14829.
6
Modern Breast Cancer Surgery 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.
Pathol Oncol Res. 2022 Jun 15;28:1610377. doi: 10.3389/pore.2022.1610377. eCollection 2022.
7
Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS.
Ann Surg Oncol. 2022 Nov;29(12):7696-7702. doi: 10.1245/s10434-022-12066-2. Epub 2022 Jun 30.

本文引用的文献

1
American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications.
Ann Diagn Pathol. 2020 Apr;45:151481. doi: 10.1016/j.anndiagpath.2020.151481. Epub 2020 Feb 15.
2
Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations.
Mod Pathol. 2020 Jul;33(7):1287-1297. doi: 10.1038/s41379-020-0459-6. Epub 2020 Jan 13.
5
6
Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experience.
Surg Oncol. 2019 Mar;28:190-194. doi: 10.1016/j.suronc.2019.01.009. Epub 2019 Jan 29.
9
Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast.
Ann Surg Oncol. 2018 Oct;25(10):3064-3068. doi: 10.1245/s10434-018-6591-6. Epub 2018 Jun 26.
10
Pleomorphic Lobular Carcinoma In Situ: Imaging Features, Upgrade Rate, and Clinical Outcomes.
AJR Am J Roentgenol. 2018 Aug;211(2):462-467. doi: 10.2214/AJR.17.19088. Epub 2018 Jun 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验